explore -WSS

explore

author：focus 2025-09-06 03:15:17 - browse：63297

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： 7 of the most gruesome medical devices in history

WSS

World's first CRISPR

Providers still hesitate to prescribe buprenorphine, study finds

Why medical students are struggling with mental health

What to know about Saharan dust affecting the US and how it can affect health

Wegovy, Zepbound and weight loss drugs that preserve muscle

Does good food count as health care? Study aims to find out

entertainment

explore

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

Wegovy, Zepbound and weight loss drugs that preserve muscle

Duchenne breakthrough therapy leaves behind pioneering families

AbbVie dramatically boosts its spending on lobbying

Bright Health sells Medicare Advantage business to Molina

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

How one medical school became remarkably diverse

Why medical students are struggling with mental health

At least 13 dead in Texas as scorching temps continue

Readout LOUD podcast: A CRISPR milestone, biotech mixology

knowledge

Marvel Studios reveals new trailer for 'The Marvels': Watch here

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

As Taiwan prepares for anti

NYU radiologists take on the challenge of expensive MRI machines

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Wikipedia

focus

explore

hotspot